SusanEDormanMD

Infectious Disease • Charleston, SC

Associate Professor of Medicine, Johns Hopkins University School of Medicine

Join to view full profile

Are you Dr. Dorman?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 75 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
171 Ashley Ave
Charleston, SC 29425
Phone+1 843-792-1414

Summary

Dr. Susan Dorman, MD is an infectious disease specialist in Charleston, South Carolina. She is currently licensed to practice medicine in South Carolina and Maryland. She is affiliated with MUSC Health University Medical Center and is an Associate Professor of Medicine at Johns Hopkins University School of Medicine.

Education & Training

National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1996 - 1999
Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
Duke University School of MedicineClass of 1993

Certifications & Licensure

SC State Medical License 2017 - 2025
MD State Medical License 1996 - 2018
American Board of Internal Medicine Infectious Disease

Clinical Trials

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment Start of enrollment: 2006 Feb 01
Completed
Phase 2
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment Start of enrollment: 2008 Dec 01
Completed
Phase 2
Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Study of Daily Rifapentine for Pulmonary Tuberculosis Start of enrollment: 2010 Apr 01
Completed
Phase 2
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers Start of enrollment: 2010 Apr 01
Completed
Phase 1
Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis Start of enrollment: 2011 Jan 01
Unknown status
Not Applicable
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis Start of enrollment: 2012 Oct 01
Completed
Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa Start of enrollment: 2011 Apr 01
Unknown status
Not Applicable
Join now to see all

Publications & Presentations

PubMed

28 citations
Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
Maunank Shah, David W. Dowdy, Moses Joloba, Willy Ssengooba, Yukari C. Manabe
AIDS. 2013-11-28
290 citations
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Su...
Payam Nahid, Susan E Dorman, Narges Alipanah, Pennan M Barry, Jan L Brozek
Clinical Infectious Diseases. 2016-10-01
2 citations
Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy ...
Yingda L Xie, Christie Eichberg, Nchimunya Hapeela, Elizabeth Nakabugo, Irene Anyango
The Lancet. Microbe. 2024-06-01

Press Mentions

Shorter TB Treatment Regimen Demonstrates EfficacyMay 6th, 2021
Program to Present Ideas for Ending TB EpidemicMarch 12th, 2021
MUSC Physician Wins $9.9 Million Contract to Run Trials for the Tuberculosis Trials ConsortiumFebruary 23rd, 2021
Join now to see all

Grant Support

Phase II Study Of Daily Rifapentine For Pulmonary Tuberculosis (Ind 62,611;1/2/0Food And Drug Administration2009–2011
Extensively Drug-Resistant Tuberculosis Among GOLD Miners In South AfricaNational Institute Of Allergy And Infectious Diseases2008–2011
Rapid Detection Of Mycobacterium TuberculosisNational Institute Of Allergy And Infectious Diseases2003–2007
Mycobacterium Tuberculosis Cell Wall Virulence FactorsNational Institute Of Allergy And Infectious Diseases2003–2004